What you need to know to pass the FRCS Vascular Surgery

Document Sample
What you need to know to pass the FRCS Vascular Surgery Powered By Docstoc
					What you need to know to pass
the FRCS – Vascular Surgery
         David Mitchell




                           Rule 1:
                           Stay awake
            KISS
• Keep it simple stupid
  – Listen to the question with
    care
  – “Surgical pause”
  – Tell them what you know,
    don’t make it up on the
    hoof.
  – Its easy to kill the unfit
    with an operation
• Don’t get lost in minutiae
  unless you are expert
                       Topics
• Core                        • Specialist
  – Aneurysms                   – Carotid in detail
     • Aortic                        • Trial data
     • Popliteal                     • Techniques and
  – PAD                                justification
     • Medical                  – Juxta-renal &Thoraco-
     • Surgery/Intervention       abdominal aneurysms
  – Amputation                       • Debranching
                                       procedures
  – Venous                      –   TOS
     • VVs
                                –   Hyperhidrosis
     • Ulcers
  – Vascular access             –   Vasculitic syndromes
  – Carotid                     –   Lymphoedema
                                –   Vascular malformations
               Evidence base
• You need to be able to talk
  sensibly about this
  – Detail for the committed
• Aortic aneurysms
  – What size to intervene
    (small AAA trial)
  – Benefits of EVAR (EVAR 1 &
    2, DREAM)
  – Screening, why should we do
    it?
                                  AAA
• Small aneurysm trial
   – RCT surgery vs watch & wait 4.0 – 5.5.cm
       • No benefit from early surgery, watch and wait is safe
       • Mortality rates about 6%
                                                              Lancet 1998 Nov 21;352(9141):1649-55

• EVAR trials (AAA of 5.5 cm or more)
   – EVAR 1 RCT in fit patients, EVAR vs OR. 1082 pts
       • Mortality 1.6% (EVAR) vs 4.6% (OR) at 30 days
                                                             Lancet 2004 Sep 4-10;364(9437):843-8
   – EVAR 2 RCT in unfit, EVAR vs no intervention. 338 pt
       • 9% op mortality (EVAR). No difference in mortality or AAA mortality at 4
         years between EVAR or no intervention
                                                       Lancet 2005 Jun 25-Jul 1;365(9478):2187-92

• DREAM – Dutch RCT EVAR vs OR 345 pts
   – >5cm AAA. 30 day mortality, EVAR 1.2% vs 4.6% in OR
                                                          N Engl J Med 2004 Oct 14;351(16):1607-18
   – At 2 years mortality EVAR 2.1% vs 5.7% OR
       • All difference accounted for by peri-op difference
                                                         N Engl J Med 2005 Jun 9;352(23):2398-405
         Screening for AAA         0·
                                   4


• DoH is introducing national screening
  programme, throughout England by 2013
• Evidence base
  – MASS trial 67,770 men 65-74 randomized to
    screening (with fu surveillance for those with AA)
    or control
     • 155 vs 296 AA related deaths over 10 years (48% RR)
     • £7600 per life year gained.
                                        BMJ 2009 Jun 24;338:b2307
                   Carotid
• Surgery for symptomatic disease
  – Clear benefits in those with tight ipsilateral
    ICA stenosis
                                       NASCET & ECST trials

  – Significant benefit in asymptomatic with tight
    stenosis
                                                 ACST trial

  – Trend to better outcome with local
    anaesthesia
                                                 GALA trial

  – Stenting not safer than surgery
                                      ICSS & CAVATAS trials
                       PAD

• Claudication
       – No one dies of it. The treatment is
         medical in the first instance.
       – Stop smoking, take anti-platelets and
         statins, exercise
  – Evidence
    • Mild to moderate symptoms
       – MIMIC trial 93 pts RCT of PTA vs
         supervised exercise
           » At 24 months better AWD for
             PTA in both fem-pop and aorto-
             iliac groups
       Eur J Vasc Endovasc Surg 2008 Dec;36(6):680-8
                             PAD
• Severe limb ischemia
  – If low ankle pressure (60 mmHg),
    limb loss more likely
• Critical limb ischemia
  – Need to be able to define: Limb loss
    very likely or inevitable
     • BASIL trial, 452 pts RCT Surgery first
       vs PTA first, endpoint was amputation
       free survival
           » At 6 months no difference in end point
             with PTA first being cheaper
                     Lancet 2005 Dec 3;366(9501):1925-34
                    PAD
• Summary
 – Medical treatment is good for all:
   • Prevention of secondary problems (MI/CVA etc)
   • Preventing deterioration in symptoms
 – Intervention for:
   • Those with threatened livelyhood
   • Severe symptoms
   • Those with threatened limb
               Amputation
• Done when:
  – Limb unsalvageable and:
    • To relieve pain
    • To remove useless/harmful limb
    • To improve mobility
• Avoid amputation in the dying
                     Venous
• Varicose veins
  – Treatment shifting from surgery to
    endovascular
     • VNUS, radiofrequency ablation, heat vein to 120oC
     • LASER, same process using light
     • Foam sclerotherapy, sclerosant mixed with air to
       create foam, larger surface area treated
  – Local anaesthesia, ablation similar success to
    surgery in destroying GSV without groin
    incision
  – Foam – about 75 – 85% success, side effects
    include visual disturbance. Concerns about CVA
    risk
                     Venous ulcers
• Beware, can find out weak candidate
   – Leg, usually venous, some other rare
     conditions
   – Foot, arterial/diabetes
• Work from first principles
   – What is the arterial supply – Doppler
     pressures
   – Scan veins
   – Compress those with ABPI >0.8
• Surgery – ESCHAR Trial
   – Does not heal ulcers, reduces recurrence over
     compression alone in SVI/mixed SV/DVI
                           Lancet 2004 Jun 5;363(9424):1854-9
                                 BMJ 2007 Jul 14;335(7610):83
              Vascular Access
• Fastest growing surgical procedure in
  Western World (? Competition from lap
  banding)
   – Providing access to circulation for:
      • Dialysis
      • Plasma filtration (hypercholesterolaemia, auto
        antibodies etc)
   – Join end of vein to side of artery
      • Use non-dominant limb, do it 6 months pre-
        dialysis
      • Synthetic grafts have higher revision rates and
        more sepsis prone
      • Central venous catheters carry highest sepsis
        risk
   – Key point for patient care
      • Need well organised team approach to deliver
        efficient service
       http://www.renal.org/pages/media/Publications/VascAccessJWP0
                                                             906.pdf
       Sub speciality areas
• Carotid
  – You will be expected to give a detailed
    interpretation of current trials.
• Thoraco-abdominal aneurysms
  – Understanding of issues around suitability
    for EVAR, role of hybrid procedures,
    debranching procedures for arch placement
    of stents
      Thoracic outlet syndrome
• Lots of confusion
  – Arterial, rare
     • Abnormal pulses, stenosis and
       post stenotic dilatation X-ray
       and scan
  – Neurological more common
     • History, X-ray for C Rib. Roos
       test
  – Venous, also common
     • Physically active, venous
       thrombosis, may benefit from
       early thrombolysis and 1st rib
       resection
        Vasculitis
• Talk coherently
  – keep away from detailed
    management issues unless
    familiar with them.
• Medical management is
  mainstay
  – Surgery/interventional
    approach reserved for those
    with severe complications
    (bleeding/necrosis) and
    quiescent disease (PTA/bypass
    in Takayashu’s arteritis)
            The unusual
• Even experts ask for help when faced
  with something unusual
              Lymphoedema
• Primary
  – Occurs without obvious cause, may present in
    adult life
    • Relative absence of lymphatic drainage
       – Manage with compression, MLD and support groups,
         surgery for severe cases
• Secondary
  – Most commonly after cancer surgery or due to
    nodal recurrence
  – Infective causes in subtropical areas
    • Treatment aimed at eradicating cause, plus as for
      primary
     Vascular malformations
• Complex area
  – Try and identify if primarily:
    • High flow (i.e. Significant arterial component)
    • Low flow (mainly venous)
    • Lymphatic component
• Management
  – Need well organised MDT
    • Avoid intervening in those who do not need it.
    • Beware the high flow ones, can be
      extraordinarily complex and difficult to manage
             Summary
• Most questions will focus on core
  topics
• Exploration of sub-speciality areas
  when core subjects covered
  – Or if candidate invites it!
• Stay focussed
  – Think of the patient and avoiding
    harm

				
DOCUMENT INFO
Shared By:
Categories:
Stats:
views:86
posted:6/20/2011
language:English
pages:21